Acute Respiratory Distress Syndrome and septic shock in pregnant woman with COVID-19

Jesselyn Kristanti, Fransiscus OH Prasetyadi

Abstract views = 143 times | downloads = 62 times


Objectives: To prove that pregnancy do not worsen the clinical course of COVID-19 compared with nonpregnant individuals as found in the first case of COVID-19 pregnant woman died in our center.

Case Report: A 27-year-old female, G2P0A1 23/24 weeks without comorbidities, complaint of diarrhea and 4 days later got fever, cough, and dyspnea. She was referred to our hospital for further evaluation because of deterioration. SARS CoV-2 RT-PCR tested positive. Blood, sputum, and urine cultures tested negative. She was intubated and given LMWH. She was worsened rapidly despite being on intensive care for 3 days with last vital signs recorded: blood pressure 66/24 mmHg with vasopressors, heart rate 136 beats/minutes, temperature 41°C, oxygen saturation 62%, cardiac arrest and expired.

Conclusion:COVID-19 pregnant women need proper care so that they will not fall into conditions such as ARDS and septic shock. Close monitoring on clinical and laboratory course is recommended. We suggest clinicians to be aware so as rapid deterioration and death can be avoided.



COVID-19; pregnant woman; ARDS; septic shock

Full Text:



World Health Organization (WHO). Clinical Management of COVID-19 Interim Guidance 27 May 2020 [Internet]. 2020. Available from:

Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (CoVID-19) from publicly reported confirmed cases: Estimation and application. Ann Intern Med. 2020;172(9):577–82.

Chan JFW, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet [Internet]. 2020;395 (10223):514–23. Available from: 30154-9

Vincenzo B, Lockwood CJ, Barss VA. Coronavirus disease 2019 (COVID-19): Pregnancy issues [Internet]. 2020. Available from: history_widget

Karami P, Naghavi M, Feyzi A, et al. Mortality of a pregnant patient diagnosed with COVID-19: A case report with clinical, radiological, and histopathological findings. Travel Med Infect Dis [Internet]. 2020;(March):101665. Available from:

Hantoushzadeh S, Shamshirsaz AA, Aleyasin A, et al. Maternal death due to COVID-19 disease. Am J Obstet Gynecol [Internet]. 2020; Available from: https://doi. org/10.1016/j.ajog.2020.04.030

Ahmed I, Azhar A, Eltaweel N, et al. First Covid-19 maternal mortality in the UK associated with thrombotic complications. Br J Haematol [Internet]. 2020;bjh.16849. Available from:

Jin X, Lian JS, Hu JH, et al. Epidemiological, clinical and virologi-cal characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms. Gut. 2020;1–8.

Wang D, Hu B, Hu C, et al. Clinical Character-istics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA - J Am Med Assoc. 2020;323(11) :1061–9.

Holshue ML, DeBolt C, Lindquist S, et al. First case of 2019 novel coronavirus in the United States. N Engl J Med. 2020;382(10):929–36.

Pacheco LD, Saad A. Ventilator management in critical illness. Crit Care Obstet. 2018;215–48.

Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 - Preliminary Report. N Engl J Med [Internet]. 2020; Available from: http://www.ncbi.nlm.nih. gov/pubmed/32445440

Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269–71.

Li L, Zhang W, Hu Y, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: A randomized clinical trial. JAMA [Internet]. 2020; Available from: http://www.ncbi.nlm.nih. gov/pubmed/32492084


  • There are currently no refbacks.

Copyright (c) 2021 Majalah Obstetri & Ginekologi



Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License